ESR1 and breast cancer: Based on our study, we propose the co-targeting of ERα, PI3Kα, p21, and PARP1 activities as a potentially efficient and safe strategy for blocking multiple cell survival avenues, reducing the emergence of resistance, and eventually leading to the selective death of ERα + breast cancer cells.